There’s no denying that GLP-1 medications like Ozempic and Wegovy are having a moment. You’ve probably seen the headlines, ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Novo Nordisk has been on the hunt for differentiated obesity drugs that could complement its blockbuster GLP-1 agonist ... plays a key role in a metabolic pathway regulating fat accumulation ...

Addiction and obesity share deep neurological roots. Can new treatments like GLP-1 drugs and MEAI help break the cycle?

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...